The current role of neoadjuvant chemotherapy in the management of cervical carcinoma

Outcome of International Federation of Gynecology and Obstetrics Stage IIB Cervical Cancer From 2003 to 2012

“…The main objectives of NACT are significant reduction of pathological risk factors and better prevention of metastatic diseases, the potential eradication of micrometastases, and the sufficient shrinkage of the primary tumor bulk to achieve radical operability. 11,12 Several clinical trials exploring the advantages of chemotherapy before radical surgery have shown the feasibility and the efficacy of chemotherapy in cervical cancer treatment, especially in FIGO stage IB2-IIA cervical cancer. 13Y15 International Federation of Gynecology and Obstetrics stage IIB cervical cancer is characterized by a higher number of risk factors and poor prognosis relative to earlystage cervical cancer.…”

Neoadjuvant Chemotherapy Followed by Chemoradiation in Cervical Carcinoma: A Review

“…It is suggested that chemotherapy agents' cross-resistance with radiotherapy may induce radio-resistant cellular clones' development and reduce chemoradiation efficacy. 18,19 In 2003, an individual patient data meta-analysis was published including data of more than 3000 patients. 9 This study considered 2 separated treatment comparison: first, NACT followed by local treatment versus the same local treatment, mainly radiotherapy.…”

Neoadjuvant Chemotherapy for Cervical Cancer: Rationale and Evolving Data

“…[19] However, an undesired delay in the main treatment and resistance to radiation therapy can occur after NACT. [20,21] …”